Abstract The cancer stem cell (CSC) hypothesis has been disproved in many cancers. CSCs may exist in blood cancer, while many epithelial cancers may not have CSCs but tumorinitiating cells (TICs). Several independent studies have provided strong evidence for existence of CSCs in brain, skin, and colon cancers (Mani et al.
Evidence for CSCs
Cancer stem cell (CSC) hypothesis has been proposed in several cancers [1] [2] [3] , while CSC hypothesis is still controversial [4] . Tumor-initiating cells (TICs) share features with embryonic stem cells (ESCs) present in preimplantation blastocyst-stage embryos, including expression of a pluripotency-associated transcription factor network [5, 6] ; in contrast to ESCs, TICs fail to properly control self-renewing cell division, which is a property of stem cells. Identification of the difference between normal tissue stem cells and CSCs will allow for development of novel treatments targeting at recurrent chemoresistant cancers while leaving healthy tissue stem cells unharmed. A restricted cell population propagates glioblastoma growth after chemotherapy [7] . In untransformed stem cells, self-renewal occurs through asymmetric cell division, in which one daughter cell retains the multipotent progenitor status of its parent while the other commits to a specialized cell fate.
The CSC theory holds in some studies of human leukemia. A subset of leukemic cells can cause leukemia when transplanted into immunocompromised mice, the key characteristic of CSCs (tumor initiation property). Cells with CSC characteristics are heterogeneous in human and mouse cancers. Eliminating these cells would eventually cure the patient. Destroying the bulk of a tumor while leaving behind CSCs enables CSCs to continue to self-renew leading to tumor recurrence. In published literature, the terms ''tumor initiating cells'' and ''cancer stem cells'' have been used interchangeably, and the difference is more of semantics than conceptual. Both terms have been used to describe a subpopulation of tumor cells possessing stem cell properties of self-renewal, differentiation, and the ability to give rise to heterogeneous lineages of cancer cells.
Drug resistance and tumor-initiating cells (TICs)
Most cells in bulk tumor lie idle (resting stage), whereas CSCs divide and replenish the tumor, analogous to the queen bee in a beehive. Chemotherapy kills workers in the beehive, while the queen bee replaces them with new ones. Cell plasticity allows normal tumor cells to turn into CSCs. Killing the non-TIC bulk cancer (workers) but not the queen bee (TIC) leads to hive recovery. In contrast, killing the queen bee (TIC) eradicates bad seeds (queen bees).
To eradicate TICs and prevent recurrence, one should aim to eradicate not just the queen but all worker bees too, because of the malignant potential and plasticity of other tumor cells, unlike worker bees.
CSCs are controversial
The CSC theory is controversial because the existence of CSCs relies on experiments that involve breaking down a tumor microenvironment, taking out particular cells, then transplanting them. This process does not exactly mirror natural cancer growth. To prove that transplanted cells are really CSCs, scientists need to look at individual cells and find direct evidence that they do indeed feed tumor growth within the natural environment of the body. Furthermore, the immortal strand hypothesis in stem cells was disproved, since hematopoietic stem cells do not asymmetrically segregate chromosomes (immortal strand) or retain BrdU [8] . It is controversial whether CSCs are equivalent to TICs in HCC, since several studies have disproved the CSC concept. TICs is the more accepted term in this field. The definition depends on whether the cells generate a tumor in a xenograft mouse model. To enrich cancer stem cells in vitro, the ''nonadherent sphere culture'' technique is commonly used [9, 39] .
Isolation and surface markers of liver TICs
Recent studies of HCC have centered on TICs, including their detection in HCC, identification of TIC markers, and isolation of TICs from human HCC cell lines. Compared with CD133 -cells, CD133
? cells isolated from HCC cell lines showed higher expression of CD44 (cell adhesion molecule) and CD34, but both CD133 subpopulations displayed similar expression of CD49f (integrin a6), CD90, CD29 (integrin b1), and CD117 (c-kit: gastrointestinal stroma tumor), indicating that these makers are still not definitive for TICs (Table 1 ) [10] . CD90
? cells are not present in normal liver and, when injected into immune-deficient mice, create tumors repeatedly. In human HCC and HCC cell lines, specifically CD133 ? cells, not CD133
-cells, had the ability to self-renew, create differentiated progenies, and form tumors [10] . Nevertheless, these markers are differentially expressed in other cancers, such as CD44
-/low in breast cancer [11] , CD34
? / CD38
-in acute myeloid leukemia [12] , and CD44
? in prostate cancer [13] . TICs were identified as CD117 ?
/CD133
? hepatic precursors in regenerating liver tissue [14] , and a CD45 -/CD90
? subpopulation of tumor cells in HCC [15] .
The plasticity of TICs with deregulated signaling and gene expression promotes chemoresistance. Several oncogenic signaling pathways in TICs of HCC are activated, including activated PI3K/AKT [16] , signal transducer and activator of transcription 3 (STAT3) [17, 18] , Notch [19] , Hedgehog [20, 21] , and deregulated transforming growth factor-beta (TGF-b) [22, 23] . This coincided with expression of genes associated with stem/progenitor status, such as b-catenin, NOTCH, BMI, and OCT3/4.
Virus (HBV and HCV), environmental factors (alcohol and obesity), and HCC Chronic liver damage caused by viral infection and environmental factors (such as alcohol or metabolic syndrome) can result in increased risk for HCC. To develop and improve HCC therapeutic modalities, understanding the molecular mechanisms of hepatocarcinogenesis is required [32] . In particular, chronic infection with HBV or HCV represents a major risk factor for HCC [33] . HCV affects more than 170 million people worldwide [33] [34] [35] . HCV and environmental factors (alcoholism and obesity) may induce cellular transformation by induction of chronic liver inflammation mediated by immune cells. This chronic liver inflammation leads to cell death, hepatocellular regeneration, and emergence of mutated cells that may be oncogenic (Fig. 1) . In addition, HCV may also induce cellular transformation directly via induction of oxidative stress and gene mutations, as well as alteration of cellular physiology, which may also lead to malignant cellular transformation. Indeed, HCV titer has been shown to exhibit a positive correlation with the amount of alcohol consumption [36] . We also found that TICs were highly sensitized to leptin exposure in vitro, as judged by phosphorylation of Stat3-Y705 [37] . Differential responses to extrinsic, adipocyte-derived cues may promote expansion of tumor cell subpopulations and contribute to oncogenesis [37] . Compelling evidence identifies obesity and hepatitis C virus (HCV) as comorbidity risk factors for hepatocellular carcinoma (HCC), which contains TICs. TLR4 signaling, activated by alcohol/obesity-associated endotoxemia, induces the stem marker NANOG and liver tumors in HCV nonstructural protein Ns5a transgenic (Tg) mice but not in wild-type or Ns5a Tg mice deficient in TLR4.
Are all tumor cells descended from a small population of ancestors (as TICs) or are they a mixed bag?
The established concept of ''monoclonality'' is summarized below. By using lineage tracing, individual cells were labeled by colored tags that they pass on to their daughter to identify cell ancestry. Dr. Clevers group labeled single intestinal cells with different colors. When benign tumors progressed to bowel cancer, they tended to be of a single color, implying that they arose from a single cell [38] . A solid tumor depends on a small group of cancer cells with ''stem cell-like'' properties. Treatments against CSCs would also damage normal, healthy tissue stem cells that help replenish cells following injury or in normal homeostasis. TICs play an important role in skin cancer: benign skin tumors (papillomas) all originate from a select few cells [39] .
TICs in HCC in alcoholic, obese, or hepatitis virusinfected patients
HCC is the third leading cause of cancer death in the world, accounting for more than 600,000 deaths in 2007. Understanding the mechanisms of genesis of TICs will improve therapeutics for treating hepatocellular carcinoma (HCC). Hepatitis C virus (HCV) and hepatitis B virus (HBV) are major causes of HCC. Compelling epidemiologic evidence identifies obesity and alcohol as comorbidity factors that can increase the risk of HCC in HCV patients, especially in alcoholic or obese patients. Alcoholism is associated with endotoxemia which stimulates proinflammatory cytokines and inflammation. The HCV-TLR4-NANOG signaling network is established, as alcohol/obesity-associated endotoxemia (LPS) which activates TLR4 signaling, resulting in induction of stem cell marker NANOG expression causing subsequent liver tumors [40] . Liver TICs are sensitized to leptin, and exposure of TICs to leptin increases the expression and activity of an intrinsic pluripotency-associated transcriptional network comprising STAT3, SOX2, OCT4, and NANOG [41] . These findings provide a direct link between the adipose-derived hormone leptin (obesity) and TICs. Stimulation of the pluripotency network may have significant implications for hepatocellular oncogenesis via genesis and maintenance of TICs. This article reviews the oncogenic pathways that generate TICs. Chronic HCV infection results in high frequency of HCC that displays nonmetastatic and multicentric characteristics. The molecular pathways of HCV-induced carcinogenesis may involve indirect, nonvirological factors such as induction of chronic liver inflammation and regeneration that lead to emergence of mutated cells with high proliferation rates. They may also involve virological factors such as viral gene products that stimulate production of reactive oxygen species (ROS) and expression of error-prone DNA polymerases. These different pathways highlight the complicated interplay between the virus and its host in HCV-related carcinogenesis (Fig. 1) . Taken together, the TIC population is the origin of cancer recurrence in drug-treated patients with HCC.
Summary
TICs (so-called CSCs) are key drivers of tumor growth and malignant progression with drug resistance and the origin of cancer recurrence in drug-treated patients with HCC.
Targeting TICs will open an avenue to help development of new drugs to eradicate recurrence problems.
